ghmm et al re MNTA: Another silly portion of the latest analyst report is this (from #msg-43844899):
The analyst tries to characterize a delay that has not even occurred yet as a reason for downgrading the stock! This is especially silly because the exact timing of the Markman hearing* is not a major concern for MNTA shareholders. Regardless of whether the hearing occurs in December or occurs in January, the Copaxone litigation is going to continue for a long time. In the overall scheme of things, the precise scheduling of the Markman hearing is inconsequential.
*The Markman hearing is the pre-trial conference in which the judge establishes the technical meaning of the claims in the disputed patents.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.